Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Laboratoires CTRS, 63, rue de l’Est, 92100 Boulogne-Billancourt, France, Email: ctrs@ctrs.fr
Neofordex 40 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White, oblong (11 mm × 5.5 mm) tablet with a score-line on one face. The tablet can be divided for administration of a 20 mg dose (see section 4.2). |
Each tablet contains dexamethasone acetate, equivalent to 40 mg dexamethasone.
Excipient with known effect: Each tablet contains 98.1 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Dexamethasone |
Dexamethasone is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. It has an approximately 7 times greater anti-inflammatory potency than prednisolone, another commonly prescribed corticosteroid. At high doses it reduces the immune response. |
| List of Excipients |
|---|
|
Lactose monohydrate |
10 × 1 tablets in OPA/Aluminium/PVC-Aluminium perforated unit dose blister. Pack size of 10 tablets.
Laboratoires CTRS, 63, rue de l’Est, 92100 Boulogne-Billancourt, France, Email: ctrs@ctrs.fr
EU/1/15/1053/001
Date of first authorisation: 16 March 2016
| Drug | Countries | |
|---|---|---|
| NEOFORDEX | Austria, Estonia, Finland, France, Croatia, Ireland, Italy, Lithuania, Poland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
